Clinical trials
Lung clinical trials
Below are recruiting lung clinical trials, each written for real people, not researchers. We’re tracking 2,885 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05379985RecruitingPhase 1/Phase 2
Test drug RMC-6236 for certain RAS mutations in advanced cancers
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
Orange, CaliforniaAges 18 years+ - NCT05391737Recruiting
Study of fluid in the lungs after open-water swimming
This study looks at what happens in the lungs after open-water swimming. It may help doctors better understand and recognize “swimming-induced lung fluid,” especially by using lung ultrasound when symptoms happen.
FalunAges 18 years+ - NCT05398094RecruitingPhase 2
Sotorasib for KRAS-mutant Stage III lung cancer without chemo-radiation
This Phase 2 study tests sotorasib (also called AMG510) in people with Stage III lung cancer that cannot be removed by surgery and that has a specific KRAS mutation (p.G12C). You may be able to join if you cannot safely receive chemo-radiotherapy at the same time, and the study checks whether sotorasib can help shrink or control the cancer.
Alicante, AlicanteAges 18 years+ - NCT05403151Recruiting
Healthy blood vessel and control study
This study looks at healthy adults and how their blood vessels work. It may help researchers understand normal circulation so they can better compare changes in future conditions.
Bethesda, MarylandAges 18–90 - NCT05403177Recruiting
Share your cancer data and samples for Ontario research
This study collects and combines medical records, genetic (genomic) data, and tumor/blood samples from people with cancer. It helps researchers build and improve a large “gold standard” cancer dataset that can support future studies and better understanding of cancer.
Kingston, OntarioAges 18 years+ - NCT05403554RecruitingPhase 1
Testing a new mesothelin-targeting drug for certain solid cancers
This Phase 1 study tests NI-1801, a drug designed to attach to a target on cancer cells (mesothelin). It may be given alone or with pembrolizumab to help shrink tumors in advanced cancers that have enough mesothelin on their cells.
ParisAges 18 years+ - NCT05426720Recruiting
Looking for TB lung damage risk factors and blood markers
This study looks at what increases the risk of long-term lung damage after active pulmonary tuberculosis (TB). It also tests whether certain blood or other markers can predict who is more likely to have lung problems later.
BeijingAges 25–60 - NCT05427136Recruiting
Study early lung problems after childhood cancer treatment
This study looks for early lung (breathing) problems in children after certain cancer treatments, using lung tests and sometimes MRI scans. It may help doctors spot breathing complications earlier and guide better care.
BaselAges 4–22 - NCT05431270RecruitingPhase 1/Phase 2
Test drug that targets CD73, alone or with immunotherapy
This early-stage study tests mavrostobart (an anti-CD73 antibody) to see what dose is safe and whether it can help shrink tumors. It’s studied by itself and also with a PD-1 immune therapy or chemotherapy, depending on your cancer type and prior treatments.
Huntersville, North CarolinaAges 18 years+ - NCT05435248RecruitingPhase 1/Phase 2
Study drug for advanced lung cancer with a specific EGFR change
This Phase 1/2 trial tests HS-10375, a study drug, in people with advanced or metastatic non-small-cell lung cancer (NSCLC) whose cancer has a specific EGFR mutation (C797S). It may help by targeting that mutation when standard treatments are not an option.
Guangzhou, GuangdongAges 18 years+ - NCT05454332RecruitingPhase 4
Caffeine for premature babies right after birth
This study tests whether caffeine given to very premature babies around the time they move from fetus to newborn stage can improve outcomes. It may help babies who need support as they breathe and adapt after birth.
Porto Alegre, Rio Grande do SulAges Up to 2 hours - NCT05456841Recruiting
Empathic communication training for lung cancer care
This trial tests whether training healthcare providers in empathetic communication improves their interactions with people receiving lung cancer care. You may be invited because your doctor’s clinic is participating and you meet the patient and language requirements.
Irvine, CaliforniaAges 18–100 - NCT05459116Recruiting
Record breathing effort to protect lungs during ventilation
This trial studies a way to measure how hard a patient is breathing and how the lungs and diaphragm are working while someone is on a breathing machine. The goal is to help the team use a “lung- and diaphragm-protective” ventilation strategy and see if it improves care.
Edegem, AntwerpAges 4 weeks+ - NCT05466396Recruiting
Study of early COPD lung function in adults
This study looks at lung function in people with early COPD (chronic obstructive pulmonary disease) to understand what happens over time. If you meet the lung test and health requirements, you may be able to help researchers learn how to better track and manage early COPD.
Beijing, Beijing MunicipalityAges 35–75 - NCT05473156RecruitingPhase 1/Phase 2
Study of AP203 for advanced solid tumors that grew despite treatment
This early-phase study tests AP203 (an investigational treatment) to see if it is safe and to look for signs it can shrink or control certain advanced cancers. The study includes a dose-finding part for many solid tumors, and a second part focused on specific lung and head/neck cancers that previously received PD-1/PD-L1 therapy.
TaipeiAges 18 years+ - NCT05473520RecruitingPhase 3
Doxycycline add-on therapy for lung improvement in tuberculosis
This Phase 3 trial tests whether adding doxycycline to standard TB medicine can improve lung function and reduce lung tissue damage. It aims to see if patients recover better by targeting the lung response to TB.
Kota Kinabalu, SabahAges 21 years+ - NCT05474196Recruiting
Monitoring pressures in the lungs for people with ARDS
This trial studies how pressure measurements from a special breathing and temperature monitoring system relate to fluid outside the lung blood vessels in people with ARDS. It may help doctors understand what those measurements mean and how to monitor patients more accurately.
Le Kremlin-BicêtreAges 18 years+ - NCT05490472RecruitingPhase 1/Phase 2
Study drug for advanced solid tumors that stopped responding
This early study tests a new medicine (JAB-2485) in adults with advanced solid tumors (cancers that have spread or grown locally). You may join to see if it can shrink tumors or control the disease when other treatments haven’t worked or weren’t tolerated.
Detroit, MichiganAges 18 years+ - NCT05491213Recruiting
Telehealth coaching to help decide on lung cancer screening
This trial tests a telehealth (video/phone) coaching program that helps people and their primary care teams make shared decisions about lung cancer screening. It may help you understand the benefits and downsides before choosing whether to get screened.
New Brunswick, New JerseyAges 18 years+ - NCT05492344Recruiting
Ultrasound-guided breathing support for severe lung failure
This study tests whether using an ultrasound scan to guide a breathing machine settings can improve care for people with moderate or severe ARDS, a serious lung condition. If you qualify, the team will compare the ultrasound-guided approach to standard ventilator care in the ICU.
BrusselsAges 18–100 - NCT05492682RecruitingPhase 1
First-in-human treatment for cancer using a drug injected into tumors
This Phase 1 trial tests PeptiCRAd-1, a treatment injected into a tumor, to see how safe it is and whether it can shrink cancers. It studies people whose cancer has come back or can’t be treated with standard options.
FrankfurtAges 18 years+ - NCT05498064Recruiting
Study of ensartinib for advanced ALK-positive lung cancer
This real-world study looks at how ensartinib works in people with advanced ALK-positive non-small cell lung cancer (NSCLC) whose disease has continued or worsened after ALK-targeted therapy. It may help doctors understand how well the treatment works and who benefits most in everyday care.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05517811Recruiting
Blood test changes before and after cancer surgery
This study measures a blood test (TEG) before and after surgery to see how it changes in people with certain cancers. It may help doctors better understand recovery and risk around the time of surgery.
Aurora, ColoradoAges 18–99 - NCT05532696RecruitingPhase 1/Phase 2
Testing ABT-101 for advanced solid tumors and HER2-mutant lung cancer
This study tests ABT-101, a new experimental treatment, in people with advanced solid tumors. A second part specifically looks at people with non-small cell lung cancer (NSCLC) that has HER2 mutations, to see how well the treatment works and how safe it is.
TaichungAges 18 years+
Hear when a new Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung?
- Yes. Clin2 currently lists 2,885 recruiting lung studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.